At a glance
- Originator Calosyn Pharma
- Class Antihypertensives; Antimigraines; Class IV antiarrhythmics; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules; Vasodilators
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Musculoskeletal pain
Most Recent Events
- 18 Apr 2016 No recent reports on development identified - Phase-I/II for Musculoskeletal pain in USA (Intra-articular)
- 06 Feb 2014 Calosyn Pharma terminates phase I/II trial in Musculoskeletal pain in USA (NCT01645709)
- 21 Mar 2013 Chemical structure added (USAN); str saved as MOL and PNG files